Latest News

Belite Bio doses the first patient at the Tokyo Medical Center in the Phase 2/3 DRAGON II clinical trial
Belite Bio doses the first patient at the Tokyo Medical Center in the Phase 2/3 DRAGON II clinical trial

October 9th 2024

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

National Eye Institute (NEI) awards $1.5 million grant to the Medical College of Georgia at Augusta University to study a new treatment target for diabetic retinopathy.
National Eye Institute (NEI) awards $1.5 million grant to the Medical College of Georgia at Augusta University to study a new treatment target for diabetic retinopathy.

October 9th 2024

Clearside Biomedical releases positive topline results from ODYSSEY Phase 2b Trial of suprachoroidal axitinib injectable suspension in wet AMD
Clearside Biomedical releases positive topline results from ODYSSEY Phase 2b Trial of suprachoroidal axitinib injectable suspension in wet AMD

October 9th 2024

Everads Therapy presented on first-in-human study of the Everads Injector for suprachoroidal administration at EURETINA 2024
Everads Therapy presented on first-in-human study of the Everads Injector for suprachoroidal administration at EURETINA 2024

October 9th 2024

Discovery of a common mechanistic defect and potential therapies for AMD and related macular dystrophies
Discovery of a common mechanistic defect and potential therapies for AMD and related macular dystrophies

October 8th 2024

Latest Videos

Latest News

© 2024 MJH Life Sciences

All rights reserved.